Table 4

The effect of comorbidity on standard CVD screening
Number of patients (n (%)) Unadjusted (OR (95% CI)) Age and gender adjusted (OR (95% CI))
No RA or DM 1071 (67.0) 1.00 1.00
RA only 353 (22.1) 0.96 (0.74, 1.26) 0.96 (0.72, 1.24)
DM only 127 (7.9) 12.15 (7.53, 19.61) 11.14 (6.86, 18.11)
RA +DM 48 (3.0) 14.91 (6.62, 33.61) 15.32 (6.70, 35.02)
No RA or HTN 651 (40.7) 1.00 1.00
RA only 192 (12.0) 1.11 (0.74, 1.68) 1.16 (0.77, 1.76)
HTN only 547 (34.2) 5.34 (4.11, 6.94) 4.82 (3.67, 6.35)
RA +HTN 209 (13.1) 4.36 (3.11, 6.11) 3.82 (2.70, 5.42)
No RA or HLP 800 (50.0) 1.00 1.00
RA only 267 (16.7) 1.09 (0.76, 1.58) 1.07 (0.68, 1.66)
HLP only 398 (24.9) 12.31 (9.25, 16.38) 9.78 (6.98, 12.87)
RA +HLP 134 (8.4) 11.50 (7.62, 17.35) 8.15 (5.40, 12.31)

RA – Rheumatoid arthritis; HTN – hypertension; HLP – hyperlipidaemia; OR – odds ratio; CI – confidence interval.

Monk et al.

Monk et al. BMC Family Practice 2013 14:150   doi:10.1186/1471-2296-14-150

Open Data